Facebook
X
LinkedIn
Forward
Achieving Comprehensive Care for Chronic Immune Thrombocytopenia
Up to 20% of pediatric patients and up to 70% of adult patients with immune thrombocytopenia have chronic disease, persisting for at least 12 months. Though available treatment options have seen some success, they are limited in their ability to address the underlying autoimmune platelet destruction etiology of ITP and often possess negative risk profiles. As a result, patients often live with uncontrolled hematological and non-hematological disease burden, including fatigue and cognitive impairment. Emerging therapies, such as Bruton’s tyrosine kinase inhibitors (BTKi), FcRN blockers, and other strategies, may offer more effective, durable, and safer treatment options to address the multi-faceted burden of ITP. Ensuring patients can access these novel therapies requires efforts to remain up-to-date with their supporting scientific data and understand principles for integrating treatments into practice. Through a dynamic format that integrates evidence-based presentations, panel discussions, and clinical cases, expert faculty participating in this symposium will bring evolving science to life and provide clinical insights to evolving strategies to address hematological and non-hematological ITP manifestations and improve the patient experience.
Target Audience
This activity is intended for Hematologists, Hematologists/Oncologists, NP/PA’s and other HCPs who may be involved in the management of patients with cITP.
Learning Objectives
- Recognize unmet hematological, quality of life, and long-term health needs of individual living with chronic ITP
- Evaluate the MoA and clinical data on BTKi treatments, and other novel disease-targeting treatments, for chronic ITP, considering hematological, safety, and patient-reported outcomes
- Propose practical strategies that support improved screening and assessment for fatigue, cognitive impairment, and other health related QoL outcomes in chronic ITP
- Integrate patient-centered strategies into chronic ITP management plans that foster early intervention to address uncontrolled disease, considering current and emerging therapy options, and support shared decision-making in the second-line treatment setting
Commercial Support
This activity is supported by an educational grant from Sanofi.
Faculty/speakers here...
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Attendance